# GIMEMA CLL0809 Study (BendOfa)

> **NCT01244451** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 49 (actual)

## Conditions studied

- Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or
- Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT01244451
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244451, "GIMEMA CLL0809 Study (BendOfa)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01244451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*